Compare Ascendis Pharma A/S (ASND) vs iShares Core MSCI EAFE ETF (IEFA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs iShares Core MSCI EAFE ETF — how do they compare? Ascendis Pharma A/S trades at $263.72 (market cap $17.74B), while iShares Core MSCI EAFE ETF trades at $96.35. Which is the better fit depends on your goals.
| ASND | IEFA | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $277.18 | $98.56 |
52-Week Low | $163.32 | $81.70 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
IEFA trades at $97.22, up 0.51% with a bullish technical signal from moving averages. The ETF provides developed international equity exposure excluding North America, offering diversification from US market concentration risks. Recent news highlights its competitive 0.07% expense ratio and 3.30% dividend yield compared to peers. Technical indicators show neutral oscillators but strong bullish momentum from moving averages.
The outlook remains positive given international diversification benefits and potential Fed rate cut catalysts. Key risks include currency fluctuations and developed market central bank policy shifts. With strong institutional interest and favorable analyst comparisons to broader international ETFs, IEFA presents a cost-effective developed markets exposure opportunity for US investors seeking geographic diversification.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →
